Dermatopathology Institute is categorized under Medical Labs in Torrance, CA and active since 2008.
Dermatopathology Institute was established in 2008, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 6215112 by the NAICS.
If you are seeking more information, feel free to contact Paul K Shitabata at the company’s single location by writing to 3870 Del Amo Boulevard # 507, Torrance, California CA 90503 or by phoning (424) 903-4036. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Dermatopathology Institute |
Contact Person: | Paul K Shitabata |
Address: | 3870 Del Amo Boulevard # 507, Torrance, California 90503 |
Phone Number: | (424) 903-4036 |
Website Address: | dermpathmd.com |
Annual Revenue (USD): | $1.000.000 to $2.499.999 |
Founded: | 2008 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Medical Labs |
SIC Code: | 8071 |
NAICS Code: | 6215112 |
Share This Business: |
Dermatopathology Institute was started in 2008 to provide professional Medical Labs under the SIC code 8071 and NAICS code 6215112. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Paul K Shitabata for inquiries that concern Dermatopathology Institute by calling the company number (424) 903-4036, as your correspondence is most welcome. Additionally, the physical location of the single location of Dermatopathology Institute can be found at the coordinates 33.848551,-118.354344 as well as the street address 3870 Del Amo Boulevard # 507 in Torrance, California 90503.
For its online presence, you may visit Dermatopathology Institute’s website at dermpathmd.com and engage with its social media outlets through on Twitter and on Facebook.